Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Camera probe spots hidden pancreatic lesions during surgery

NCT ID NCT03729453

Knowledge-focused Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a tiny camera called SpyGlass that doctors insert into the pancreatic duct during surgery for a condition called IPMN (a type of cyst that can turn into cancer). The goal is to see if the camera can find small, hidden tumors that standard scans miss. About 100 patients scheduled for pancreatic surgery will take part. The results will help design a larger, more definitive trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SpyGlass catheter (a tiny camera inserted into the pancreatic duct during surgery)
What this could lead to
If successful, this could help surgeons detect hidden tumors during IPMN surgery, potentially reducing the need for repeat operations.
What could go wrong
This is a small, early-stage study (100 participants) focused on gathering data, not proving a treatment works. The device may not find all lesions, and there are risks from the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Mar 2019

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for surgery for suspected MD-IPMN or Mixed IPMN resection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient scheduled for surgery for suspected MD-IPMN or Mixed IPMN within 4-6 weeks of enrollment 2. Diameter of pancreatic main duct \>5mm on pre-operative MRI or CT 3. Written informed consent from patient to participate in the study, including compliance with study procedures Exclusion Criteria: 1. Contraindication for pancreatoscopy 2. Age: less than 18 years 3. Pregnant women, evaluated per local clinical standard

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraductal papillary mucinous neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic intraductal papillary-mucinous neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraductal papillary mucinous neoplasm

Contacts and locations

Locations

  • Academic Medical Center

    Amsterdam, 1105 AZ, Netherlands

  • Asian Institute of Gastroenterology

    Hyderabad, 500-082, India

  • Indiana University Health

    Indianapolis, Indiana, 46202, United States

  • Johns Hopkins Hospital University

    Baltimore, Maryland, 21287, United States

  • Kansai Medical University

    Hirakata, Osaka, 573-1010, Japan

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, 210029, China

  • University Hospital of UMEA

    Umeå, 907 37, Sweden

  • University of Colorado Hospital

    Denver, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.